Insights from 2023 ASH Annual Meeting
Playback speed
10 seconds
Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOIA Study
By
Insights from 2023 ASH Annual Meeting
FEATURING
Paolo Ghia
By
Insights from 2023 ASH Annual Meeting
FEATURING
Paolo Ghia
31 views
March 27, 2024
Login to view comments.
Click here to Login
Leukemia